ArticleFrontiers in microbiology2021
Circulation of Extended-Spectrum Beta-Lactamase-Producing
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Mobile Genetic Elements Associated with Antimicrobial Resistance Across One Health Interfaces in Africa: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2026Review
- Third-Generation Cephalosporin-Resistant Enterobacterales and Methicillin-ResistantAnimals : an open access journal from MDPI · 2025Article
- ChronicInternational journal of molecular sciences · 2025Article
- Genotypic characterization of extended-spectrum beta-lactamase-producingMicrobiology spectrum · 2025Article
- Suppression of gut colonization by multidrug-resistant Escherichia coli clinical isolates through cooperative niche exclusion.Nature communications · 2025Article
- Survey in ruminants from Rwanda revealed high diversity and prevalence of extended-spectrum cephalosporin-resistant Enterobacterales.BMC veterinary research · 2024Article
- Occurrence of Extended-spectrum β-lactamase (ESBL) and Carbapenemase-producing Escherichia coli isolated from Childhood Diarrhoea in Yaoundé, Cameroon.BMC microbiology · 2024Article
- Carbapenem- and cefiderocol-resistantJAC-antimicrobial resistance · 2024Article
- Phenotypic and molecular characterization of beta-lactam resistant Multidrug-resistant Enterobacterales isolated from patients attending six hospitals in Northern Nigeria.Scientific reports · 2023Article
- Genomic Characterization of Multidrug-Resistant Extended Spectrum β-Lactamase-ProducingMicroorganisms · 2023Article
- Article
- Molecular Epidemiology ofMicroorganisms · 2022Article
- Emergence and Dissemination of Extraintestinal Pathogenic High-Risk International Clones ofLife (Basel, Switzerland) · 2022Review
- Multidrug-Resistant High-RiskAntibiotics (Basel, Switzerland) · 2022Article
- Highly Virulent and Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Extensively Drug-Resistant Klebsiella pneumoniae Counteracts Fitness and Virulence Costs That Accompanied Ceftazidime-Avibactam Resistance Acquisition.Microbiology spectrum · 2022Article
- Molecular Epidemiology of Extended-Spectrum Beta-Lactamase and AmpC ProducingAntibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multi-drug resistant (MDR), gram-negative
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.